Green in the sea of red: Healthcare (1)Summary
This week we are sharing 2 rebound trade opportunities in healthcare and biotech, AMEX:XLV and AMEX:XBI , which are showing relative strength against S&P500 and Nasdaq , making them better candidates to trade for rebound.
Since the beginning of 2022, skyrocketing inflation and increasing recession risk have pushed the broad equity markets to the downside. S&P500 is down more than 20% from peak, while the more tech heavy Nasdaq is down close to 30% from peak as of today. If we look back the whole rally, it all started during Mar-2020 as the Fed reacted aggressively toward covid by massive money printing (i.e. quantitative easing). In fact both S&P500 and Nasdaq are now getting closer to the 250 weeks moving average, which is approximately where the post-covid rally had broken the pre-covid peak. Rebound is very likely to happen as “where it started” is usually a strong resistance level that slows correction.
S&P500
Nasdaq100
To execute this trade, instead of directly longing the indexes, healthcare and biotech sector ETF, AMEX:XLV and AMEX:XBI are showing relative strength against S&P500 and Nasdaq100, which make them better candidates to trade the idea. Fundamentally speaking, we believe the reason behind the strength is due to the irreversible trends of aging population across the globe especially among developed countries; as well as in the seemingly more frequent pandemic outbreaks during recent years. Both trends create steady demand for healthcare and need for biotechnological innovation. The MRNA technology is a good recent example to illustrate the importance of biotechnological innovation in fighting pandemic.
We recommend more conservative traders to execute the idea with AMEX:XLV (this post), while more aggressive traders can go with AMEX:XBI (link here: ) which is relatively volatile.
Note : XBI also come with 3X leveraged ETF AMEX:LABU (bullish) and AMEX:LABD (bearish) for those who are looking for more leverage with same amount of capital
Technical
AMEX:XLV is still outperforming major indexes. Instead of downtrend, AMEX:XLV is still in a consolidation period. AMEX:XLV has been trading in extending box range since Oct-2021, with 1 extension to the upside in Dec-2021, and 1 extension to the downside this year on Jun-13.
The more than 8 months of consolidation period has flattened the 250 days moving average, yet not bending it downward (yet?). 20 days and 50 days moving averages have been crossing each other multiple times during the consolidation period, making them less indicative from a technical perspective. Currently AMEX:XLV is trading below 250 days moving average, tested but failed to penetrate the moving average on Jul-8, if it still cannot get above the 250 days moving average in the coming months, the downside pressure will materialize into an actual down trend.
In summary, these are the important levels one should pay attention to:
Downside support
118.75: Jun-13 new box bottom
109.74: Post covid peak before rallying to the upside
Upside resistance
132.04: Jul-8 attempt of breaking 250 days moving average
143.42: Apr-8 new box top
Healthcare
7/4/22 SWAVShockWave Medical, Inc. ( NASDAQ:SWAV )
Sector: Health Technology (Medical Specialties)
Market Capitalization: $7.109B
Current Price: $198.62
Breakout price: $200.15
Buy Zone (Top/Bottom Range): $194.30-$180.50
Price Target: $217.20-$221.90 (1st), $246.50-$249.80 (2nd)
Estimated Duration to Target: 38-40d (1st), 83-88d (2nd)
Contract of Interest: $SWAV 8/19/22 195c, $SWAV 10/21/22 195c
Trade price as of publish date: $19.10/contract, $26.50/contract
7/4/22 AMNAMN Healthcare Services Inc. ( NYSE:AMN )
Sector: Commercial Services (Personnel Services)
Market Capitalization: $5.130B
Current Price: $114.73
Breakout price: $115.20
Buy Zone (Top/Bottom Range): $113.95-$108.40
Price Target: $120.90-$123.70
Estimated Duration to Target: 38-40d
Contract of Interest: $AMN 8/19/22 110c
Trade price as of publish date: $10.80/contract
VEEV - uptrendAnother stock that seems to have bottomed. 10, 20, 50 MA curled up, it's a lot above 100 MA and I wouldn't be surprised if we retest around $192 and the 100 MA before we grind higher. Also, the 200MA is pretty far away so we might be moving in this range for a bit but overall, the trend looks better than other tech names.
Healthcare is bouncing bigHealthcare seems to be finally reversing with lot of momentum compared to other sectors as was expected in this high inflation environment.
June 16th tested the lows made on May 24th and this bear market seems to be bouncing back up for a correction from recent lows.
It’s quite possible healthcare sector ends up positive from here thru the year end while the rest of the sectors struggle.
How to trade $JAN for max profit today.Hi traders, we have a trading idea to share with you.
The idea is for $JAN stock. The stock is currently above $ 4 (a support level) with upward momentum after reporting patent issuance for artery treatment.
In addition, the stock has a great upside if it will break through the trend line built on the 5-minute chart.
Bullish Swing Trade on UNHWith sell in May and go away in play. I thought I'd take a swing trade on UNH it is in a defensive sector(healthcare), which is a rotation method for the summer months. So I'll place a limit order @ 489.00 and a SL @ 454.00 and a TP @ 555.00. The order block and the market cycle (May 13 - Jun 6 2022) are confirmations.
ENDP - Potential Long SetupWe are tracking the close today for ENDP. If this stock has a strong close today with a daily RSI breakout, we may see a good 30-40% Retracement.
Few items we are tracking:
Daily RSI breakout at close
GAP to be filled withing next few weeks, or sooner. (Price targets included
30% - 40% Retracement
Let us know what you thing. Good luck all.
$HUM Humana LT Chart - LEAP OptionsHumana fairly rangebound for the last six months. Tested ~$470 key resistance level six times unsuccessfully. Monitor for a breakthrough and close above this level. Once this occurs we could see an overdue strong move to the $600 area by 1H of 2024.
Long Term Target: $580-$615 range by 1H '24
I plan to play this using LEAP options. I'm looking at the $450 and $500 Jan'24 calls. If you're looking to limit risk and capital outlay, I would consider a vertical call spread buying either the $450 or $500 call and selling the $600.
Note: This is NOT investment advice. This is opinion only.
4/24/22 UNHUnitedHealth Group Inc. ( NYSE:UNH )
Sector: Health Services (Managed Health Care)
Market Capitalization: $490.152B
Current Price: $520.94
Breakout price: $536.25
Buy Zone (Top/Bottom Range): $529.50-$507.55
Price Target: $548.50-$553.30 (1st), $611.50-$618.00 (2nd)
Estimated Duration to Target: 29-31d (1st), 97-100d (2nd)
Contract of Interest: $UNH 5/20/22 520c, $UNH 9/16/22
Trade price as of publish date: $18.57/contract, $25.25/contract
HCAT LongTechnical Analysis : We broke the downtrend line and had three white soldiers to confirm the reversal of the trend, also the falling wedge shows a bullish reversal since we broke it upwards. Although on a lower timeframe MACD and RSI look bearish, we expect the price to reach our Buy Zone before the impulsive move upwards.
Aroon : Aroon Up on Top and Aroon Down on bottom show a bullish momentum.
MACD : We had lower lows on the chart but not on MACD which shows MACD divergence and signals for a reverse of the downtrend.
Entry : 21.5-23.5
Target : 39.75 (at Fib50% and just below a previous high and resistance )
Invalidation : 19.5 ( Just Below our support and last low )
NVCR primed for an extended runKept the chart simple but there are a lot of bullish aspects at play here:
- ready for markup after an accumulation phase
- coming off a wave 5 correction apprx. 0.786 off the highs last June
- looking at weekly chart you’ll see a larger running flat structure
- earnings as a catalyst and overall great company!
*Initial Target by Apr 14 = 99
** Target range by 5/20/2022 = 108-116
Would love to hear your thoughts on this.
BNTX HIGH RISK TO REWARD SETUP YOU CAN'T MISSNews - Better than expected Q4 EPS and sales results, the company expects to authorize a shares repurchase program up to 1.5B over the next two years.
Levels -$195 is the next major resistance level.
$138 is the next major support level.
The stock is gapping up to $183 (pre-market).
The idea is to go long at the open when it will try to test the $183 support level and fail, then go long above the 5M bull flag pattern if it will happen.
3/20/22 REGNRegeneron Pharmaceuticals, Inc. ( NASDAQ:REGN )
Sector: Health Technology (Pharmaceuticals: Major)
Market Capitalization: $74.451B
Current Price: $685.94
Breakout price: $687.00
Buy Zone (Top/Bottom Range): $660.50-$603.40
Price Target: $812.00-$816.40
Estimated Duration to Target: 125-130d
Contract of Interest: $REGN 9/16/22 700c
Trade price as of publish date: $50.35/contract
3/13/22 LLYEli Lilly and Company ( NYSE:LLY )
Sector: Health Technology (Pharmaceuticals: Major)
Market Capitalization: $253.61B
Current Price: $266.30
Breakout price: $270.95 (hold above)
Buy Zone (Top/Bottom Range): $262.45-$247.10
Price Target: $308.00-$310.40
Estimated Duration to Target: 84-90d
Contract of Interest: $LLY 6/17/22 300c
Trade price as of publish date: $5.90/contract
Anthem, Inc. $ANTM flashing a VCPAnthem, Inc. is a provider of health insurance in the United States and is ranked 23rd on the Fortune 500. Fundamentals are very strong, it has an average YoY revenue growth of +14% for the las three quarters, and the last two quarters had EPS and Margin growth over the hundreds.
IBD is giving NYSE:ANTM a #1 rank in its industry group and a 94 relative strength rating. That is synonymous of good fundamentals accompanied by very good technicals. Relative to the NASDAQ, the index has done three lower lows as NYSE:ANTM has done three higher lows. That is the kind of action a future leader does.
Also, if you compare it against its sector AMEX:XLV , is doing way better.
For the las 5 weeks, the price has been making a classic VCP with a pivot buy above $472. Today had a bad close but with low volume, that is a good sign. But, as the market is still in a correction, breakouts aren't working very well. Is time to be cautios so, if the breakout happens I'll buy 1/4 of my typical position sizing.
an often mentioned healthcare stock (PFE)pfizer is one of those household names that has been getting constant attention since the outbreak of covid 19. right now it is at the tail end of a long downtrend, and healthcare is acting as a defensive play for risk off rotation. as long as the broader market bounces this should bounce.